Quick Dispatch:
Your surmount study tirzepatide EASD 22: SURMOUNT-MMO: Tirzepatide in Obese Type II Diabetes Patients orders ship within 1-2 business days.
Delivery Options:
Order Tracking:
You'll receive a tracking link by email once your surmount study tirzepatide EASD 22: SURMOUNT-MMO: Tirzepatide in Obese Type II Diabetes Patients ships.
Need Help?
Questions about surmount study tirzepatide EASD 22: SURMOUNT-MMO: Tirzepatide in Obese Type II Diabetes Patients, sizing, or delivery? We're just an email away.
Live Shipping Estimates:
Enter your location at checkout to see available shipping methods and costs for surmount study tirzepatide EASD 22: SURMOUNT-MMO: Tirzepatide in Obese Type II Diabetes Patients in your area.
Tirzepatide and blood pressure reduction: stratified analyses of the SURMOUNT-1 randomised controlled trial
22.85
Nutritional status with tirzepatide in obesity: A post hoc analysis of the SURMOUNT-1-4 randomized clinical trials
28.66
ECO 2026: SURMOUNT-MAINTAIN proves tirzepatide sustains weight loss long term
27.08
00377-2/asset/984f48c3-9a91-4eba-8a7d-d724f5e65288/main.assets/gr2_lrg.jpg)
Efficacy and safety of once-weekly tirzepatide in Japanese patients with obesity disease (SURMOUNT-J): a multicentre, randomised, double-blind, placebo-controlled phase 3 trial
25.35
SURMOUNT-5: Tirzepatide shows superior weight loss over semaglutide
23.47
Tirzepatide weight-loss study shows promising results
27.78
Tirzepatide shows 47% greater weight loss vs. Wegovy
28.70
